OKYO Pharma Limited (OKYO)

NASDAQ: OKYO · Real-Time Price · USD

1.680

-0.030 (-1.75%)

At close: Mar 12, 2026, 4:00 PM EDT

1.700

+0.020 (1.19%)

After-hours: Mar 12, 2026, 4:10 PM EDT

OKYO Pharma Employees

OKYO Pharma had 4 employees as of March 31, 2025. The number of employees increased by 1 or 33.33% compared to the previous year.

Employees

4

Change (1Y)

1

Growth (1Y)

33.33%

Revenue / Employee

n/a

Profits / Employee

-$1,153,335

Market Cap

86.30M

Employees Chart

Employees History

Date	Employees	Change (1Y)	Growth (1Y)
Mar 31, 2025	4	1	33.33%
Mar 31, 2024	3	-5	-62.50%
Mar 31, 2023	8	1	14.29%
Mar 31, 2022	7	1	16.67%
Mar 31, 2021	6	2	50.00%
Mar 31, 2020	Upgrade Pro	Upgrade Pro	Upgrade Pro
Mar 31, 2019	Upgrade Pro	Upgrade Pro	Upgrade Pro

Related Stocks

Company Name	Employees
Pliant Therapeutics	171
PolyPid	73
aTyr Pharma	65
PMV Pharmaceuticals	47
Q32 Bio	26
iBio, Inc.	20
MAIA Biotechnology	13
Cingulate	13

Employee Rankings

OKYO News

17 days ago - OKYO Abstract Selected for Presentation at Premier Global Ophthalmology Congress - GlobeNewsWire
4 weeks ago - OKYO Pharma Announces Pricing of $20 Million Public Offering of Ordinary Shares - GlobeNewsWire
4 weeks ago - OKYO Pharma Announces Public Offering of Ordinary Shares - GlobeNewsWire
4 weeks ago - OKYO Pharma Announces Transition of At-The-Market Equity Offering Facility to Leerink Partners - GlobeNewsWire
4 weeks ago - OKYO Pharma Strengthens World Class Leadership Team with Appointment of Flavio Mantelli, MD, PhD as Chief Medical Officer - GlobeNewsWire
5 weeks ago - OKYO Pharma Announces Acceptance of Urcosimod Phase 2 Study Results for Presentation at Prestigious ASCRS Annual Meeting - GlobeNewsWire
6 weeks ago - OKYO Pharma Announces Successful Type C Meeting with the FDA - GlobeNewsWire
6 weeks ago - FDA Approves Compassionate Use of Urcosimod (0.05%) for the Treatment of Neuropathic Corneal Pain - GlobeNewsWire